Expanding the Scope of Treatment for Borderline Personality Disorder

被引：2
|
作者：
Paris, Joel [1 ]
机构：
[1] McGill Univ, Inst Community & Family Psychiat, Montreal, PQ H3T 1E4, Canada
来源：
JOURNAL OF NERVOUS AND MENTAL DISEASE | 2013年 / 201卷 / 02期
关键词：
RANDOMIZED CONTROLLED-TRIAL; DELIBERATE SELF-HARM; FOLLOW-UP; WOMEN;
D O I：
10.1097/NMD.0b013e31827f64c8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：143 / 144
页数：2
相关论文
共 50 条
  • [1] Treatment of Borderline Personality Disorder
    Levy, Kenneth N.
    McMain, Shelley
    Bateman, Anthony
    Clouthier, Tracy
    [J]. PSYCHIATRIC CLINICS OF NORTH AMERICA, 2018, 41 (04) : 711 - +
  • [2] The treatment of borderline personality disorder
    Eckert, J
    Dulz, B
    Makowski, C
    [J]. PSYCHOTHERAPEUT, 2000, 45 (05): : 271 - 285
  • [3] Treatment of borderline personality disorder
    Mountain, D
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2006, 188 : 493 - 493
  • [4] Treatment of borderline personality disorder
    Shapiro, ER
    Plakun, EM
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (11): : 1645 - 1646
  • [5] Borderline Personality Disorder Barriers to Borderline Personality Disorder Treatment and Opportunities for Advocacy
    Tusiani-Eng, Paula
    Yeomans, Frank
    [J]. PSYCHIATRIC CLINICS OF NORTH AMERICA, 2018, 41 (04) : 695 - +
  • [6] Integrated treatment for borderline personality disorder
    Oldham, John M.
    [J]. PSYCHIATRIC ANNALS, 2006, 36 (05) : 361 - +
  • [7] Psychopathology and treatment of borderline personality disorder
    Bohus, M.
    Schmahl, C.
    [J]. NERVENARZT, 2007, 78 (09): : 1069 - 1080
  • [8] Treatment and prevention of borderline personality disorder
    Taubner, Svenja
    [J]. PSYCHOTHERAPEUT, 2020, 65 (05): : 329 - 330
  • [9] Venlafaxine in the treatment of borderline personality disorder
    Markovitz, PJ
    Wagner, SC
    [J]. PSYCHOPHARMACOLOGY BULLETIN, 1995, 31 (04) : 773 - 777
  • [10] Quetiapine in the treatment of borderline personality disorder
    Hilger, E
    Barnas, C
    Kasper, S
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S329 - S329
12345